JRP
FATE icon

Jasper Ridge Partners’s Fate Therapeutics FATE Stock Holding History

Jasper Ridge Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-7,394
Closed -$287K – 149
2022
Q1 		$287K Hold
7,394
– – 0.01% 132
2021
Q4 		$433K Sell
7,394
-11,818
-62% -$670K 0.02% 122
2021
Q3 		$1.14M Buy
19,212
+15,515
+420% +$1.22M 0.05% 96
2021
Q2 		$321K Hold
3,697
– – 0.02% 117
2021
Q1 		$305K Hold
3,697
– – 0.01% 106
2020
Q4 		$336K Buy
+3,697
New +$230K 0.01% 100

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Jasper Ridge Partners's FATE Position: Q2 2022 in Review

Jasper Ridge Partners sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 7,394 shares — an estimated $287K sold.

Jasper Ridge Partners first reported a position in FATE in Q4 2020 and held it in 6 quarters. The position peaked at $1.14M in Q3 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • Jasper Ridge Partners reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jasper Ridge Partners sold 7,394 Fate Therapeutics shares in Q2 2022, an estimated $287K.
  • Jasper Ridge Partners first reported a position in Fate Therapeutics in Q4 2020 and held it in 6 quarters.
  • Jasper Ridge Partners's Fate Therapeutics position peaked at $1.14M in Q3 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on Jasper Ridge Partners's 13F filing for Q2 2022, filed 15 Aug 2022.